When Hyperkalemia Impairs Optimal Treatment o...

Discover the patients who need timely treatment for metabolic dysfunction–associated steatohepatitis (MASH). How will you find them? And then what will you do? Credit available for this activity expires: [12/30/26] Earn Credit / Learning Objectives & Disclosures: https://www.meds ...  Show more

Alarming in immunoglobulin A nephropathy (IgAN): over 40% present late. Explore latest advancements in management of the most common cause of primary glomerulonephritis worldwide. Credit available for this activity expires: 12/23/26 Earn Credit / Learning Objectives & Disclosures ...  Show more

Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF), but it is not consistently improved by any of the current guideline-directed medical therapies. JAMA Deputy Editor Gregory Curfman, MD, discusses whether omecamtiv mecarbil ca ...  Show more

The following question refers to Section 7.3 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. The question is asked by Palisades Medical Center medicine resident & CardioNerds Academy Fellow Dr. Maryam Barkhordarian, answered first by Hopkins Bayview medici ...  Show more

In this episode, we review new updates and key concepts from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. This guideline is newly published (April 2022) and is a full update of the 2013 guidelines and the 2017 focused update for heart failure. Key Concepts ...  Show more

The following question refers to Section 4.4 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Maryam Barkhordarian, answered first by medicine resident Dr. Ahmed Ghoneem, and then by expert faculty Dr. Noreen Nazir. Dr. Nazir is Assistant Professor of Clinic ...  Show more